Combination of a lanthanum compound and bone enhancing agent for the treatment of bone diseases

Abstract

The invention provides a method for enhancing bone formation, inhibiting osteoclastic differentiation and/or activating osteoblastic differentiation whereby to manage, treat or achieve prophylaxis of bone disease which comprises administering to a human or animal subject suffering from, or susceptible to bone disease a therapeutically or prophylactically effective amount of a lanthanum compound and a bone enhancing agent, such as vitamin D.

1 . A pharmaceutical composition for the treatment or prevention of a bone deficit condition or bone remodeling disorder comprising a lanthanum (III) compound and a bone enhancing agent.  
   
   
       2 . A composition according to  claim 1 , wherein the lanthanum (III) compound is a lanthanum salt, a lanthanum chelate, a lanthanum resin, a lanthanum absorbent, or a mixture thereof.  
   
   
       3 . A composition according to  claim 2 , wherein the lanthanum (III) compound is the lanthanum salt, wherein the lanthanum salt is a lanthanum carbonate, a lanthanum carbonate hydrate, a lanthanum chloride, or a mixture thereof.  
   
   
       4 . A composition according to  claim 3 , wherein the lanthanum (III) salt is the lanthanum carbonate hydrate.  
   
   
       5 . A composition according to  claim 1 , wherein the bone enhancing agent is a synthetic hormone, a natural hormone, estrogen, calcitonin, tamoxifen, a bisphosphonate, a bisphosphonate analog, vitamin D, a vitamin D analog, a mineral supplement, a statin drug, a selective estrogen receptor modulator, a sodium fluoride, or a mixture thereof.  
   
   
       6 . A composition according to  claim 5 , wherein the bone enhancing agent is vitamin D.  
   
   
       7 . A composition according to  claim 1 , wherein the lanthanum (III) compound is lanthanum carbonate tetrahydrate and the bone enhancing agent is vitamin D.  
   
   
       8 . A composition according to  claim 1 , wherein the lanthanum (III) compound is present in the composition in an amount from about 125 mg to about 1000 mg as elemental lanthanum.  
   
   
       9 . A composition according to  claim 6 , wherein the bone enhancing agent is 25-hydroxy vitamin D 2  and is present in the composition in an amount of up to about 1 mg.  
   
   
       10 . A composition according to  claim 6 , wherein the bone enhancing agent is 1,25-dihydroxy vitamin D 2  and is present in the composition in an amount of up to about 1 mg.  
   
   
       11 . A pharmaceutical dosage for the treatment or prevention of a bone deficit condition or bone remodeling disorder comprising a lanthanum (III) compound and a bone enhancing agent, wherein the lanthanum (III) compound and the bone enhancing agent are in separate dosage forms.  
   
   
       12 . The pharmaceutical dosage of  claim 11 , wherein the bone enhancing agent is vitamin D.